Your browser doesn't support javascript.
loading
Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan.
Senoh, Mitsutoshi; Kato, Haru; Honda, Hitoshi; Fukuda, Tadashi; Tagashira, Yasuaki; Horiuchi, Hiroko; Chiba, Hiroshi; Suzuki, Daisuke; Hosokawa, Naoto; Kitazono, Hidetaka; Norisue, Yasuhiro; Kume, Hisashi; Mori, Nobuaki; Morikawa, Hideo; Kashiwagura, Saeko; Higuchi, Akiko; Kato, Hideaki; Nakamura, Makoto; Ishiguro, Saori; Morita, Sayuri; Ishikawa, Hideaki; Watanabe, Takuya; Kojima, Katsuyuki; Yokomaku, Izumi; Bando, Tatsuya; Toimoto, Kayoko; Moriya, Kei; Kasahara, Kei; Kitada, Seigo; Ogawa, Junko; Saito, Haruko; Tominaga, Harumi; Shimizu, Yousuke; Masumoto, Fumi; Tadera, Kayoko; Yoshida, Junichi; Kikuchi, Tetsuya; Yoshikawa, Ichiro; Watanabe, Tatsuyuki; Honda, Masahisa; Yokote, Kuniko; Toyokawa, Takao; Miyazato, Hiroko; Nakama, Mika; Mahe, Cedric; Reske, Kimberly; Olsen, Margaret A; Dubberke, Erik R.
Afiliação
  • Senoh M; Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kato H; Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan. Electronic address: cato@nih.go.jp.
  • Honda H; Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Fukuda T; Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Tagashira Y; Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Horiuchi H; Hachinohe City Hospital, Aomori, Japan.
  • Chiba H; Hachinohe City Hospital, Aomori, Japan.
  • Suzuki D; Kameda Medical Center, Chiba, Japan.
  • Hosokawa N; Kameda Medical Center, Chiba, Japan.
  • Kitazono H; Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
  • Norisue Y; Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
  • Kume H; Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
  • Mori N; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Morikawa H; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kashiwagura S; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Higuchi A; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kato H; Toyokawa City Hospital, Aichi, Japan.
  • Nakamura M; Toyokawa City Hospital, Aichi, Japan.
  • Ishiguro S; Toyokawa City Hospital, Aichi, Japan.
  • Morita S; Toyokawa City Hospital, Aichi, Japan.
  • Ishikawa H; Tokai Central Hospital, Gifu, Japan.
  • Watanabe T; Tokai Central Hospital, Gifu, Japan.
  • Kojima K; Tokai Central Hospital, Gifu, Japan.
  • Yokomaku I; Tokai Central Hospital, Gifu, Japan.
  • Bando T; Tokai Central Hospital, Gifu, Japan.
  • Toimoto K; Nara Medical University, Nara, Japan.
  • Moriya K; Nara Medical University, Nara, Japan.
  • Kasahara K; Nara Medical University, Nara, Japan.
  • Kitada S; National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
  • Ogawa J; National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
  • Saito H; National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
  • Tominaga H; National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
  • Shimizu Y; National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
  • Masumoto F; National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
  • Tadera K; National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
  • Yoshida J; Shimonoseki City Hospital, Yamaguchi, Japan.
  • Kikuchi T; Shimonoseki City Hospital, Yamaguchi, Japan.
  • Yoshikawa I; University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.
  • Watanabe T; University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.
  • Honda M; University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.
  • Yokote K; University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.
  • Toyokawa T; Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
  • Miyazato H; Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
  • Nakama M; Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
  • Mahe C; Sanofi Pasteur, Lyon, France.
  • Reske K; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Olsen MA; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Dubberke ER; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Anaerobe ; 60: 102107, 2019 Dec.
Article em En | MEDLINE | ID: mdl-31647977
ABSTRACT

BACKGROUND:

The optimal and practical laboratory diagnostic approach for detection of Clostridioides difficile to aid in the diagnosis of C. difficile infection (CDI) is controversial. A two-step algorithm with initial detection of glutamate dehydrogenase (GDH) or nucleic acid amplification test (NAAT) alone are recommended as a predominant method for C. difficile detection in developed countries. The aim of this study was to compare the performance of enzyme immunoassays (EIA) detecting toxins A and B, NAAT detecting the toxin B gene, and GDH compared to toxigenic culture (TC) for C. difficile as the gold standard, in patients prospectively and actively assessed with clinically significant diarrhea in 12 medical facilities in Japan.

METHODS:

A total of 650 stool specimens were collected from 566 patients with at least three diarrheal bowel movements (Bristol stool grade 6-7) in the preceding 24 h. EIA and GDH were performed at each hospital, and NAAT and toxigenic C. difficile culture with enriched media were performed at the National Institute of Infectious Diseases. All C. difficile isolates recovered were analyzed by PCR-ribotyping.

RESULTS:

Compared to TC, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of EIA were 41%, 96%, 75% and 84%, respectively, and for NAAT were 74%, 98%, 91%, and 92%, respectively. In 439 specimens tested with GDH, the sensitivity, specificity, PPV, and NPV were 73%, 87%, 65%, and 91%, and for an algorithm (GDH plus toxin EIA, arbitrated by NAAT) were 71%, 96%, 85%, and 91%, respectively. Among 157 isolates recovered, 75% of isolates corresponded to one of PCR-ribotypes (RTs) 002, 014, 018/018", and 369; RT027 was not isolated. No clear differences in the sensitivities of any of EIA, NAAT and GDH for four predominant RTs were found.

CONCLUSION:

The analytical sensitivities of NAAT and GDH-algorithm to detect toxigenic C. difficile in this study were lower than most previous reports. This study also found low PPV of EIAs. The optimal method to detect C. difficile or its toxins to assist in the diagnosis of CDI needs further investigation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Técnicas Bacteriológicas / Infecções por Clostridium Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Anaerobe Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Técnicas Bacteriológicas / Infecções por Clostridium Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Anaerobe Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão